Minocycline taken during concurrent chemoradiation therapy for non-small cell lung cancer (NSCLC) patients significantly reduced patient-reported fatigue, according to preliminary findings presented at the 2016 American Society of Clinical Oncology (ASCO) meeting.1

For this double-blind, phase 2 trial, investigators enrolled 49 patients with NSCLC scheduled to undergo chemoradiotherapy at a single institution. Participants were randomly assigned to receive minocycline 100 mg orally twice daily or placebo over the course of chemoradiation. Demographic and disease characteristics were similar between the 2 arms.

Results showed that the entire sample reported a significant increase in fatigue during chemoradiotherapy (P = .0002).

Researchers found that minocycline was associated with a significant reduction in patient-reported fatigue after chemoradiation (P < .0001), as well as significantly less fatigue over 12 weeks (P = .025), in contrast with placebo. No grade 3 or worse treatment-related adverse events were reported.

“These preliminary results are encouraging and warrant a phase 3 trial to test its efficacy,” the authors concluded.

Reference

  1. Cleeland CS, Shi Q, Wang XS, Mendoza TR, Williams LA, Liao ZX, et al. Minocycline to reduce chemoradiation-related fatigue in patients with non-small cell lung cancer: A phase II randomized trial. J Clin Oncol. 2016; 34 (suppl; abstr 10017).